Trial Profile

A Phase 2, Single-Blind, Exploratory, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Daily Oral NYX-2925 in Subjects With Fibromyalgia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NYX 2925 (Primary)
Indications Fibromyalgia
Focus Biomarker; Pharmacodynamics
Sponsors Aptinyx

Most Recent Events

26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
28 Oct 2019 Results published in the Aptinyx media release
28 Oct 2019 According to an Aptinyx media release, data from this study has been selected as a late-breaking poster presentation at the American College of Rheumatology Annual Meeting. ePoster to be presented at ACR Annual Meeting on Tuesday, November 12

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com